RHE · Regional Health Properties, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $53.16M | $18.34M | $17.16M | $35.92M | $26.69M | $17.58M |
| Cost of Revenue | $6.98M | - | - | - | - | - |
| Gross Profit | $46.18M | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $12.04M | $5.41M | $3.98M | $4.65M | $3.90M | $3.37M |
| Total Operating Expenses | $54.20M | $18.17M | $17.97M | $42.75M | $24.11M | $15.29M |
| D&A | $2.06M | $2.06M | $2.25M | $2.40M | $2.59M | $2.89M |
| Operating Income | $1.66M | $161.0K | ($804.0K) | ($6.82M) | $2.58M | $2.29M |
| Interest Expense | $2.67M | $2.71M | $2.75M | $2.53M | $2.67M | $2.78M |
| Income Tax | $108.0K | - | - | - | - | - |
| Net Income | $3.04M | ($3.22M) | ($3.89M) | ($6.87M) | ($1.18M) | ($688.0K) |
| EPS - Basic | $1.09 | ($1.73) | $21.05 | ($5.87) | - | - |
| EPS - Diluted | $1.09 | ($1.73) | $21.05 | ($5.87) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.00M | $582.0K | $1.00M | $800.0K | $6.80M | $4.20M |
| Accounts Receivable | $8.03M | $3.36M | $1.40M | $6.29M | $2.15M | $2.10M |
| Inventory | $1.35M | - | - | - | - | - |
| Accounts Payable | $3.69M | - | - | - | - | - |
| Current Assets | $6.82M | - | - | - | - | - |
| Total Assets | $67.81M | $60.47M | $62.18M | $68.58M | $105.70M | $108.03M |
| Current Liabilities | $20.41M | - | - | - | - | - |
| Long-term Debt | $34.74M | $49.72M | $50.73M | $52.18M | $52.88M | $54.44M |
| Total Liabilities | $62.77M | $63.38M | $62.00M | $64.86M | $95.30M | $96.92M |
| Stockholders' Equity | $349.0K | ($2.92M) | $185.0K | $3.72M | $10.40M | $11.10M |
| Retained Earnings | ($81.78M) | ($85.12M) | ($81.90M) | ($121.41M) | ($114.54M) | ($113.36M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.26M) | $1.94M | $3.71M | ($3.60M) | $4.89M | $1.29M |
| Investing Cash Flow | $15.10M | ($530.0K) | ($958.0K) | ($281.0K) | ($123.0K) | ($450.0K) |
| Financing Cash Flow | ($10.25M) | ($2.13M) | ($2.48M) | ($2.06M) | ($2.42M) | ($1.39M) |
| CapEx | $869.0K | $530.0K | $958.0K | $281.0K | $123.0K | $450.0K |
| Free Cash Flow | ($3.13M) | $1.41M | $2.75M | ($3.88M) | $4.77M | $845.0K |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.9% | - | - | - | - | - |
| Operating margin | 3.1% | 0.9% | -4.7% | -19.0% | 9.7% | 13.0% |
| EBITDA margin | 7.0% | 12.1% | 8.5% | -12.3% | 19.4% | 29.5% |
| Net margin | 5.7% | -17.6% | -22.7% | -19.1% | -4.4% | -3.9% |
| Free cash flow margin | -5.9% | 7.7% | 16.0% | -10.8% | 17.9% | 4.8% |
| FCF / Net income | -1.03 | -0.44 | -0.71 | 0.56 | -4.04 | -1.23 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 22.7% | 29.5% | 23.2% | 12.9% | 14.6% | 19.2% |
| Effective tax rate | 3.4% | - | - | - | - | - |
| Return on assets | 4.5% | -5.3% | -6.3% | -10.0% | -1.1% | -0.6% |
| Return on equity | 872.5% | 110.2% | -2101.6% | -184.8% | -11.4% | -6.2% |
| Return on invested capital | 4.6% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.33 | - | - | - | - | - |
| Quick ratio | 0.27 | - | - | - | - | - |
| Cash ratio | 0.15 | - | - | - | - | - |
| Leverage | ||||||
| Debt / Equity | 99.54 | -17.03 | 274.24 | 14.04 | 5.09 | 4.90 |
| Debt / Assets | 0.51 | 0.82 | 0.82 | 0.76 | 0.50 | 0.50 |
| Debt / EBITDA | 9.32 | 22.37 | 34.97 | - | 10.23 | 10.49 |
| Interest coverage | 0.6x | 0.1x | -0.3x | -2.7x | 1.0x | 0.8x |
| Equity multiplier | 194.30 | -20.71 | 336.11 | 18.46 | 10.17 | 9.73 |
| Liabilities / Assets | 0.93 | 1.05 | 1.00 | 0.95 | 0.90 | 0.90 |
| Efficiency | ||||||
| Asset turnover | 0.78 | 0.30 | 0.28 | 0.52 | 0.25 | 0.16 |
| Inventory turnover | 5.16 | - | - | - | - | - |
| Days sales outstanding | 55d | 67d | 30d | 64d | 29d | 44d |
| Days inventory outstanding | 71d | - | - | - | - | - |
| Days payable outstanding | 193d | - | - | - | - | - |
| Cash conversion cycle | -67d | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 189.9% | 6.8% | -52.2% | 34.6% | 51.8% | -12.7% |
| Revenue CAGR (3y) | 14.0% | -11.8% | -0.8% | 21.3% | 6.6% | -11.3% |
| Revenue CAGR (5y) | 24.8% | -1.9% | -4.9% | 7.4% | -0.5% | -0.9% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 933.5% | - | 88.2% | - | 12.4% | -58.0% |
| Net income growth (YoY) | - | 17.2% | 43.4% | -481.0% | -71.8% | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -48.7% | - | - | 464.6% | -63.9% |
| FCF CAGR (5y) | - | -9.6% | 22.2% | - | - | - |
| Book value growth (YoY) | - | - | -95.0% | -64.3% | -6.4% | -5.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$53.16M totalHealthcare Services Segment$36.05M · 67.8%
Pharmacy Service$11.72M · 22.1%
Real Estate Segment$5.39M · 10.1%
Product / service
$53.16M totalHealth Care Patient Service$36.05M · 67.8%
Pharmacy Revenues$11.71M · 22.0%
Rental Revenue$5.40M · 10.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.30
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- -Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Lessors of Real Property, NEC
Comparing REGIONAL HEALTH PROPERTIES against the 5 most active filers in the same SIC group.